logo-loader
viewVolitionRx

VolitionRx well positioned as it enters Q2 after strengthening balance sheet

Cameron Reynolds, chief executive of VolitionRx Limited (NYSE AMERICAN:VNRX), tells Proactive London's Andrew Scott they're in a good place after again strengthening the balance sheet in recent weeks with a further $5 million in warrants exercised for cash.

''Total cash in hand that gives us around $21.2mln ... so it's a really good runway to get our milestones completed''.

Reynolds also updates on operational developments including their first large-scale lung cancer study being carried out in Taiwan.

Quick facts: VolitionRx

Price: - -

NYSEMKT:VNRX
Market: NYSEMKT
Market Cap: -
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of VolitionRx named herein, including the promotion by the Company of VolitionRx in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

VolitionRx acquires epigenetic reagent company Octamer GmbH

VolitionRx Limited's (NYSEAMERICAN:VNRX) Cameron Reynolds talks through the rationale for its acquisition of epigenetic reagent company Octamer GmbH. Reynolds says they're paying around €650,000 euros ($725,000) in cash and stock and the deal is expected to close in January 2020. 

4 weeks, 2 days ago

2 min read